Literature DB >> 17506480

High-molecular intestinal alkaline phosphatase by agarose gel electrophoresis.

Kinue Ooi1, Katsuya Shiraki, Yoshitaka Morishita, Tsutomu Nobori.   

Abstract

The presence of high-molecular intestinal ALP (HIALP) overlapping with bone ALP in the alpha(2)beta region has been demonstrated. In this study we evaluated a method of separating HIALP after its conversion into ALP(5) by the action of protease. Serum samples from patients were mixed with protease at a ratio of 5:1 and left at room temperature for more than 30 min. The protease-treated and nontreated samples were both subjected to agarose gel electrophoresis. Patients who showed a decrease in ALP(3) in the alpha2beta region and an increase in ALP(5) in the beta region were regarded as HIALP-positive. HIALP was observed in 26.7-33.1% of patients with liver diseases, collagen diseases, and diabetes mellitus. Renal disease was ABO blood group-dependent and showed high positive rates for blood groups B and O. The HIALP-positive rate was low (7.1-15.5%) in patients with cardiovascular diseases, malignant tumors, and other disorders. ALP(5) was also observed in 98.4% of HIALP-positive patients with liver diseases. In patients with collagen diseases or diabetes mellitus, the positive rate of ALP(5) was 40.4-66.7%. In conclusion, this method, in which HIALP is converted into ALP(5) by protease pretreatment and is separated from bone ALP, allows HIALP to be identified while other fractions remain unaffected. (c) 2007 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17506480      PMCID: PMC6649042          DOI: 10.1002/jcla.20179

Source DB:  PubMed          Journal:  J Clin Lab Anal        ISSN: 0887-8013            Impact factor:   2.352


  11 in total

1.  Identification of intestinal, intestinal variant, and high-Mr alkaline phosphatase with the resolve-ALP isoelectric focusing system.

Authors:  V O Van Hoof; M F Hoylaerts; M Van Mullen; L G Lepoutre; M E De Broe
Journal:  Clin Chem       Date:  1991-02       Impact factor: 8.327

2.  Kasahara-variant alkaline phosphatase in a renal cell carcinoma.

Authors:  T Hada; K Higashino; T Okochi; Y Yamamura
Journal:  Clin Chim Acta       Date:  1978-10-16       Impact factor: 3.786

3.  Multiple forms of human intestinal alkaline phosphatase: chemical and enzymatic properties, and circulating clearances of the fast- and slow-moving enzymes.

Authors:  T Komoda; Y Sakagishi; T Sekine
Journal:  Clin Chim Acta       Date:  1981-12-09       Impact factor: 3.786

4.  Improved agarose electrophoretic method for separating alkaline phosphatase isoenzymes in serum.

Authors:  V O Van Hoof; L G Lepoutre; M F Hoylaerts; R Chevigné; M E De Broe
Journal:  Clin Chem       Date:  1988-09       Impact factor: 8.327

5.  Influence of diet on the "intestinal" component of serum alkaline phosphatase in people of different ABO blood groups and secretor status.

Authors:  M J Langman; E Leuthold; E B Robson; J Harris; J E Luffman; H Harris
Journal:  Nature       Date:  1966-10-01       Impact factor: 49.962

6.  Specific gel electrophoresis method detects two isoforms of human intestinal alkaline phosphatase.

Authors:  M Matsushita; T Irino; K Oh-le; T Komoda
Journal:  Electrophoresis       Date:  2000-01       Impact factor: 3.535

7.  Intestinal variant alkaline phosphatase in plasma in disease.

Authors:  T Kuwana; S B Rosalki
Journal:  Clin Chem       Date:  1990-11       Impact factor: 8.327

8.  Age and sex distribution of alkaline phosphatase isoenzymes by agarose electrophoresis.

Authors:  V O Van Hoof; M F Hoylaerts; H Geryl; M Van Mullem; L G Lepoutre; M E De Broe
Journal:  Clin Chem       Date:  1990-06       Impact factor: 8.327

9.  A fetal intestinal-type alkaline phosphatase in hepatocellular carcinoma tissue.

Authors:  K Higashino; R Otani; S Kudo; Y Yamamura
Journal:  Clin Chem       Date:  1977-09       Impact factor: 8.327

10.  Intestinal type alkaline phosphatase hyperphosphatasemia associated with liver cirrhosis.

Authors:  S Saheki; M Ochi; T Horiuchi; Y Sakagishi; Y Fujimori-Arai; I Koyama; T Komoda; N Takeuchi
Journal:  Clin Chim Acta       Date:  1992-09-15       Impact factor: 3.786

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.